Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warns Apotex Management To Demand Quality, Meet Specs

Executive Summary

Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.

You may also be interested in...



Some Pointers From The US FDA On How To Conduct Better Out-Of-Spec Investigations

Industry is still having major problems in this area despite the FDA's exhaustive 2006 OOS guidance.

Apotex Withdraws 31 ANDAs After Failing To Ensure Data Integrity At Two Indian Manufacturing Plants

Persistent data integrity and quality unit failures at two Apotex plants in Bangalore, India, led to wholesale US market withdrawals by the Canadian generic drug manufacturer.

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel